The economics of lung cancer management in Canada

Lung Cancer

Volumn 14, Issue 1, 1996, Pages 19-29

  Evans, W K ^a,b   Will, B P ^c   Berthelot, J M ^c   Wolfson, M C ^c,d  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c STATISTICS CANADA   (Canada)

^d CANADIAN INSTITUTE FOR ADVANCED RESEARCH   (Canada)

Author keywords

Cost; Health economics; Lung cancer; Microsimulation model

Indexed keywords

ARTICLE; CANADA; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HUMAN; LUNG CANCER; PRIORITY JOURNAL;

EID: 0029935583     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-5002(95)00510-2     Document Type: Article

References (26)

1. Wolfson MC. POHEM - A framework for understanding and modeling the health of human populations. Presented at Bureau of the Census 1992 Annual Research Conference, Arlington, Virginia. In: Proceedings of the Annual Research Conference, 1992; 261-282.
2. National Cancer Institute of Canada. Canadian cancer statistics 1994. Toronto, Canada: National Cancer Institute of Canada, 1994.
3. Evans WK, Will BP, Berthelot J-M, Wolfson MC. Estimating the cost of lung cancer diagnosis and treatment in Canada: The POHEM Model. Can J Oncol, 1995; 5: 408-417.
4. Evans WK, Will BP, Berthelot J-M, Wolfson MC. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Brit J Cancer 1995; 72: 1270-1277.
5. Evans WK, Feld R, Murray N et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 1987; 107: 451-458.
6. Rapp R, Pater JL, Willan A et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer. Report of a Canadian multicentre randomized trial. J Clin Oncol 1988; 6: 633-641.
7. Mountain CM, Gail MH for The Lung Cancer Study Group: Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 1981; 82: 649-657.
8. Holmes EC, Gail MH for The Lung Cancer Study Group: Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 1986; 4: 710-715.
9. Johnson DH, Einhorn LH, Bartolucci A et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 1990; 113: 33-38.
10. Perez CA, Stanley K, Rubin P et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung: preliminary report by the Radiation Therapy Oncology Group. Cancer 1980; 45: 2744-2753.
11. Feld R, Evans WK, Coy P et al. Canadian multicentre randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 1987; 5: 1401-1409.
12. Statistics Canada. Annual Return of Hospitals - Hospital Indicators 1988-89; Catalogue 83-233. Ottawa, Canada: Statistics Canada, Government of Canada, Supply and Service, Ottawa, Canada.
13. Goodwin PJ, Feld R, Evans WK, Pater J. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol 1988; 6: 1537-1547.
14. Jaakkimainen L, Goodwin PJ, Pater J et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol 1990; 8: 1301-1309.
15. Wodinsky H, Jenkin RDT. The cost of radiation treatment at an Ontario regional cancer centre. Can Med Assoc J 1987; 137: 906-909.
16. Roswit B, Patno ME, Rapp R et al. The survival of patients with inoperable lung cancer: a large-scale randomized trial of radiation therapy versus placebo. Radiology 1968; 90: 688-697.
17. Carroll M, Morgan SA, Yarnold JR et al. Prospective evaluation of a watch policy in patients with inoperable non-small cell lung cancer. Eur J Cancer Clin Oncol 1986; 22: 1353-1356.
18. Hansen HH, Dombernowsky P and Hirsch F. Staging procedures and prognostic features in small cell anaplastic bronchogenic carcinoma. Semin Oncol 1979; 5(3): 280-287.
19. Dillman RO, Seagren SL, Propert KJ et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. New Engl J Med 1990; 323: 940-945.
20. Le Chevalier M, Arriagada R, Quoix E et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-small cell lung cancer: first analysis of a randomized trial of 353 patients. J Natl Cancer Inst 1991; 83: 417-423.
21. Sause W, Scott C, Taylor S et al. RTOG 8808, ECOG 4588: Preliminary analysis of a phase III trial in regionally advanced unresectable non-small cell lung cancer. Proc Am Soc Clin Oncol 1994; 13: 325 (Abstr 1072).
22. Schaake-Koning C, Van Den Bogaert W, Dalesio O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. New Engl J Med 1992; 326: 524-530.
23. Pignon J-P, Stewart LA, Souhami RL, Arriagada R, on behalf of the NSCLC Collaborators Group (NSCLCCG), Institut Gustave-Roussy. A meta-analysis using individual patient data from randomized clinical trials (RCTS) of chemotherapy (CT) in non-small cell lung cancer (NSCLC): (2) Survival in the locally advanced (LA) setting. Proc Am Soc Clin Oncol 1994; 13: 334 (Abstr 1109).
24. Souquet PJ, Chauvin F, Boissel JP et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19-21.
25. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small cell lung cancer: How much benefit is enough? J Clin Oncol 1993; 11: 1866-1872.
26. Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 1991; 114: 798-802.